Pioneers of the world’s first TCR therapy

We are a commercial-stage T cell receptor (TCR) biotechnology company that is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune diseases.

Latest news

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Immunocore announces transition of Chief Financial Officer

Immunocore reports second quarter financial results and provides a business update

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

* Intended for investors and members of the media.

Latest Presentation

Corporate Presentation – September 2024

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024

Latest Annual Report

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR contacts

Headquarters

Immunocore Holdings plc
Immunocore Limited
92 Park Drive
Milton Park
Abingdon, Oxon OX14 4RY
UK
T: +44 (0)1235 438600
info@immunocore.com

Investor relations

Clayton Robertson
Head of Investor Relations
T: +1 (215) 384-4781
ir@immunocore.com

Transfer agent

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol, BS99 6ZZ
United Kingdom
T: 0370 703 0387